2X9N
High resolution structure of TbPTR1 in complex with cyromazine
Summary for 2X9N
Entry DOI | 10.2210/pdb2x9n/pdb |
Related | 2C7V 2VZ0 2WD7 2WD8 2X9V 3BMC 3BMD 3BME 3BMF 3BMG 3BMH 3BMI 3BMJ 3BMK 3BML 3BMM 3BMN 3BMO 3BMQ 3BMR 3GN1 3GN2 |
Descriptor | PTERIDINE REDUCTASE, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, N~2~-cyclopropyl-1,3,5-triazine-2,4,6-triamine, ... (8 entities in total) |
Functional Keywords | short chain dehydrogenase, oxidoreductase |
Biological source | TRYPANOSOMA BRUCEI BRUCEI |
Total number of polymer chains | 4 |
Total formula weight | 127031.48 |
Authors | Dawson, A.,Tulloch, L.B.,Barrack, K.L.,Hunter, W.N. (deposition date: 2010-03-23, release date: 2010-06-30, Last modification date: 2024-05-08) |
Primary citation | Dawson, A.,Tulloch, L.B.,Barrack, K.L.,Hunter, W.N. High-Resolution Structures of Trypanosoma Brucei Pteridine Reductase Ligand Complexes Inform on the Placement of New Molecular Entities in the Active Site of a Potential Drug Target Acta Crystallogr.,Sect.D, 66:1334-, 2010 Cited by PubMed Abstract: Pteridine reductase (PTR1) is a potential target for drug development against parasitic Trypanosoma and Leishmania species. These protozoa cause serious diseases for which current therapies are inadequate. High-resolution structures have been determined, using data between 1.6 and 1.1 Å resolution, of T. brucei PTR1 in complex with pemetrexed, trimetrexate, cyromazine and a 2,4-diaminopyrimidine derivative. The structures provide insight into the interactions formed by new molecular entities in the enzyme active site with ligands that represent lead compounds for structure-based inhibitor development and to support early-stage drug discovery. PubMed: 21123874DOI: 10.1107/S0907444910040886 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.15 Å) |
Structure validation
Download full validation report